vs
FEDERATED HERMES, INC.（FHI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是FEDERATED HERMES, INC.的1.3倍（$622.0M vs $479.0M），Royalty Pharma plc净利率更高（34.4% vs 20.1%，领先14.3%），Royalty Pharma plc同比增速更快（4.8% vs -0.8%），过去两年FEDERATED HERMES, INC.的营收复合增速更高（9.1% vs 4.6%）
方德贺明是总部位于美国宾夕法尼亚州匹兹堡的投资管理机构，成立于1955年，1957年10月18日正式注册。截至2025年12月，公司受托管理客户资产规模达9026亿美元，可为客户提供股票、固定收益、另类/私募市场、多资产及流动性管理等多元投资策略，产品覆盖共同基金、ETF、独立账户、封闭式基金和集合投资基金等品类。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FHI vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$479.0M
营收增速更快
RPRX
高出5.6%
-0.8%
净利率更高
RPRX
高出14.3%
20.1%
两年增速更快
FHI
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $479.0M | $622.0M |
| 净利润 | $96.4M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 26.4% | 62.4% |
| 净利率 | 20.1% | 34.4% |
| 营收同比 | -0.8% | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FHIRPRX
| Q1 26 | $479.0M | — | ||
| Q4 25 | $482.8M | $622.0M | ||
| Q3 25 | $469.4M | $609.3M | ||
| Q2 25 | $424.8M | $578.7M | ||
| Q1 25 | $423.5M | $568.2M | ||
| Q4 24 | $424.7M | $593.6M | ||
| Q3 24 | $408.5M | $564.7M | ||
| Q2 24 | $402.6M | $537.3M |
净利润FHIRPRX
| Q1 26 | $96.4M | — | ||
| Q4 25 | $107.0M | $214.2M | ||
| Q3 25 | $104.1M | $288.2M | ||
| Q2 25 | $91.0M | $30.2M | ||
| Q1 25 | $101.1M | $238.3M | ||
| Q4 24 | $84.7M | $208.2M | ||
| Q3 24 | $87.5M | $544.0M | ||
| Q2 24 | $21.0M | $102.0M |
营业利润率FHIRPRX
| Q1 26 | 26.4% | — | ||
| Q4 25 | 28.1% | 62.4% | ||
| Q3 25 | 27.6% | 70.1% | ||
| Q2 25 | 27.6% | 36.3% | ||
| Q1 25 | 31.1% | 94.0% | ||
| Q4 24 | 26.0% | 60.9% | ||
| Q3 24 | 27.4% | — | ||
| Q2 24 | 10.1% | 50.2% |
净利率FHIRPRX
| Q1 26 | 20.1% | — | ||
| Q4 25 | 22.2% | 34.4% | ||
| Q3 25 | 22.2% | 47.3% | ||
| Q2 25 | 21.4% | 5.2% | ||
| Q1 25 | 23.9% | 41.9% | ||
| Q4 24 | 19.9% | 35.1% | ||
| Q3 24 | 21.4% | 96.3% | ||
| Q2 24 | 5.2% | 19.0% |
每股收益（稀释后）FHIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $1.38 | $0.49 | ||
| Q3 25 | $1.34 | $0.67 | ||
| Q2 25 | $1.16 | $0.07 | ||
| Q1 25 | $1.25 | $0.55 | ||
| Q4 24 | $1.08 | $0.46 | ||
| Q3 24 | $1.06 | $1.21 | ||
| Q2 24 | $0.20 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $348.4M | $9.0B |
| 股东权益账面价值 | $100.8B | $9.7B |
| 总资产 | $2.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.00× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FHIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $582.5M | $618.7M | ||
| Q3 25 | $506.3M | $938.9M | ||
| Q2 25 | $371.0M | $631.9M | ||
| Q1 25 | $387.6M | $1.1B | ||
| Q4 24 | $504.4M | $929.0M | ||
| Q3 24 | $375.0M | $950.1M | ||
| Q2 24 | $307.4M | $1.8B |
总债务FHIRPRX
| Q1 26 | $348.4M | — | ||
| Q4 25 | $348.4M | $9.0B | ||
| Q3 25 | $348.3M | $8.9B | ||
| Q2 25 | $348.2M | $8.0B | ||
| Q1 25 | $348.2M | $7.6B | ||
| Q4 24 | $348.1M | $7.6B | ||
| Q3 24 | $348.0M | $7.6B | ||
| Q2 24 | $348.0M | $7.6B |
股东权益FHIRPRX
| Q1 26 | $100.8B | — | ||
| Q4 25 | $1.2B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.1B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $1.0B | $9.8B |
总资产FHIRPRX
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.2B | $19.6B | ||
| Q3 25 | $2.2B | $19.3B | ||
| Q2 25 | $2.2B | $18.3B | ||
| Q1 25 | $2.0B | $17.6B | ||
| Q4 24 | $2.1B | $18.2B | ||
| Q3 24 | $2.0B | $18.0B | ||
| Q2 24 | $1.9B | $17.7B |
负债/权益比FHIRPRX
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.29× | 0.92× | ||
| Q3 25 | 0.29× | 0.93× | ||
| Q2 25 | 0.31× | 0.84× | ||
| Q1 25 | 0.32× | 0.78× | ||
| Q4 24 | 0.32× | 0.74× | ||
| Q3 24 | 0.32× | 0.74× | ||
| Q2 24 | 0.34× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FHIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $297.3M | $827.1M | ||
| Q3 25 | $103.1M | $702.6M | ||
| Q2 25 | $18.8M | $364.0M | ||
| Q1 25 | $14.3M | $596.1M | ||
| Q4 24 | $346.6M | $742.5M | ||
| Q3 24 | $117.1M | $703.6M | ||
| Q2 24 | $88.7M | $658.2M |
自由现金流FHIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $294.6M | — | ||
| Q3 25 | $101.6M | — | ||
| Q2 25 | $18.0M | — | ||
| Q1 25 | $13.3M | — | ||
| Q4 24 | $342.5M | — | ||
| Q3 24 | $114.1M | — | ||
| Q2 24 | $82.7M | — |
自由现金流率FHIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 61.0% | — | ||
| Q3 25 | 21.6% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 3.1% | — | ||
| Q4 24 | 80.7% | — | ||
| Q3 24 | 27.9% | — | ||
| Q2 24 | 20.5% | — |
资本支出强度FHIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 1.5% | — |
现金转化率FHIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 2.78× | 3.86× | ||
| Q3 25 | 0.99× | 2.44× | ||
| Q2 25 | 0.21× | 12.06× | ||
| Q1 25 | 0.14× | 2.50× | ||
| Q4 24 | 4.09× | 3.57× | ||
| Q3 24 | 1.34× | 1.29× | ||
| Q2 24 | 4.22× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FHI
| Investment advisory fees, net | $319.4M | 67% |
| Administrative service fees, net-affiliates | $110.3M | 23% |
| Other | $49.3M | 10% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
